Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.
Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano C, Levis A, Federico M, Angrilli F, Di Giulio G, Corazza GR. Gobbi PG, et al. Among authors: bonfante v. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):396-402. doi: 10.1016/j.clml.2011.04.008. Epub 2011 Jun 12. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21729691
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. Viviani S, et al. Among authors: bonfante v. N Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340. N Engl J Med. 2011. PMID: 21774708 Free article. Clinical Trial.
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM. Viviani S, et al. Among authors: bonfante v. Leuk Lymphoma. 2010 Jul;51(7):1251-9. doi: 10.3109/10428194.2010.486090. Leuk Lymphoma. 2010. PMID: 20528244 Clinical Trial.
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G. Visco C, et al. Among authors: bonfante v. Eur J Haematol. 2006 Nov;77(5):387-94. doi: 10.1111/j.1600-0609.2006.00725.x. Epub 2006 Jul 27. Eur J Haematol. 2006. PMID: 16879607
Vinorelbine: a new promising drug in Hodgkin's disease.
Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Devizzi L, et al. Among authors: bonfante v. Leuk Lymphoma. 1996 Aug;22(5-6):409-14. doi: 10.3109/10428199609054778. Leuk Lymphoma. 1996. PMID: 8882953 Review.
63 results